HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (17) Citing Articles via Google Scholar Google Scholar Articles by Takamura, N. Articles by Otagiri, M. Search for Related Content PubMed PubMed Citation Articles by Takamura, N. Articles by Otagiri, M. Related Collections Drug Monitoring and Toxicology

Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia

¹ Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kumamoto University, 5–1 Oe-honmachi, Kumamoto 862, Japan.

² Department of Pharmacy, Miyazaki Medical College Hospital, Kiyatake-cho, Miyazaki 889–16, Japan.
^a Author for correspondence. Fax +81-96-362-7690; e-mail Otagirim{at}gpo

To elucidate the mechanism of impaired serum binding of furosemide observed in patients with renal dysfunction, we examined in vitro the serum protein binding of furosemide in the absence and presence of uremic toxins that are endogenously retained solutes in uremic serum and act as inhibitors of drug binding. Analysis of the binding data of furosemide at its therapeutic concentration (6.6 mg/L) indicated that, among the four uremic toxins studied, 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) showed the greatest inhibitory potency for the binding of furosemide to serum; moreover, the inhibition was competitive. CMPF thus most likely represents the primary determinant for the serum binding defect of furosemide in uremia. However, CMPF and oleate appear to exert a synergistic effect on the inhibition of furosemide serum binding—perhaps through a cascade effect on furosemide-binding inhibition in the oleate–CMPF–furosemide system, in which the binding of oleate to its low-affinity sites indirectly displaces furosemide from albumin and thus increases the transiently liberated CMPF molecules. Similar cascade effects on furosemide binding in the presence of CMPF were also originated by other long-chain (C₁₈) fatty acids, linoleate and stearate, although to a lesser extent. Because CMPF is not effectively removed by ordinary hemodialysis treatment, the combined direct and cascade effects of CMPF and fatty acids appear to contribute to the increase in the free fraction of furosemide during hemodialysis.

The following articles in journals at HighWire Press have cited this article:

				T. Nishio, N. Takamura, R. Nishii, J. Tokunaga, M. Yoshimoto, and K. Kawai Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2304 - 2310. [Abstract] [Full Text] [PDF]

				N. Takamura, T. Maruyama, E. Chosa, K. Kawai, Y. Tsutsumi, Y. Uryu, K. Yamasaki, T. Deguchi, and M. Otagiri BUCOLOME, A POTENT BINDING INHIBITOR FOR FUROSEMIDE, ALTERS THE PHARMACOKINETICS AND DIURETIC EFFECT OF FUROSEMIDE: POTENTIAL FOR USE OF BUCOLOME TO RESTORE DIURETIC RESPONSE IN NEPHROTIC SYNDROME Drug Metab. Dispos., April 1, 2005; 33(4): 596 - 602. [Abstract] [Full Text] [PDF]

				H. Sun, Y. Huang, L. Frassetto, and L. Z. Benet EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN Drug Metab. Dispos., November 1, 2004; 32(11): 1239 - 1246. [Abstract] [Full Text] [PDF]

				C.-F. Lim and J. R. Stockigt Influence of Uremic Toxins and Nonesterified Fatty Acids on Drug and Thyroid Hormone Binding in Serum Clin. Chem., November 1, 1998; 44(11): 2380 - 2381. [Full Text] [PDF]